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ABSTRACT: Tight glycemic control (TGC) has shown benefits in ICU patients, but been difficult to 
achieve consistently due to inter- and intra- patient variability that requires more adaptive, patient-
specific solutions. STAR (Stochastic TARgeted) is a flexible model-based TGC framework account-
ing for patient variability with a stochastically derived maximum 5% risk of blood glucose (BG) be-
low 72mg/dL. This research describes the first clinical pilot trial of the STAR approach and the post-
trial analysis of the models and methods that underpin the protocol. 
 
The STAR framework works with clinically specified targets and intervention guidelines. The clinical-
ly specified glycemic target was 125mg/dL. Each trial was 24 hours with BG measured 1-2 hourly. 
Two-hourly measurement was used when BG was between 110-135mg/dL for 3 hours. In the STAR 
approach, each intervention leads to a predicted BG level and outcome range (5-95th percentile) based 
on a stochastic model of metabolic patient variability. Carbohydrate intake (all sources) was moni-
tored, but not changed from clinical settings except to prevent BG < 100mg/dL when no insulin was 
given. Insulin infusion rates were limited (6U/hour maximum), with limited increases based on current 
infusion rate (0.5-2.0U/hour), making this use of the STAR framework an insulin-only TGC approach. 
Approval was granted by the Ethics Committee of the Medical Faculty of the University of Liege 
(Liege, Belgium). 
 
Nine patient trials were undertaken after obtaining informed consent. There were 205 measurements 
over all 9 trials. Median [IQR] per-patient results were: BG: 138.5 [130.6 - 146.0] mg/dL; Carbohy-
drate Administered: 2-11 g/hour; Median Insulin: 1.3 [0.9 – 2.4] U/hour with a maximum of 6.0 [4.7 – 
6.0] U/hour. Median [IQR] time in the desired 110-140 mg/dL band was: 50.0 [31.2 - 54.2]%. Median 
model prediction errors ranged: 10-18%, with larger errors due to small meals and other clinical 
events. The minimum BG was 63mg/dL and no other measurement was below 72 mg/dL, so only 1 
measurement (0.5%) was below the 5% guaranteed minimum risk level.  
 
Post-trial analysis showed that patients were more variable than predicted by the stochastic model used 
for control, resulting in some of the prediction errors seen. Analysis and (validated) virtual trial re-
simulating the clinical trial using stochastic models relevant to the patient’s particular day of ICU stay 
were seen to be more accurate in capturing the observed variability. This analysis indicated that equiv-
alent control and safety could be obtained with similar or lower glycemic variability in control using 
more specific stochastic models. 
 
STAR effectively controlled all patients to target. Observed patient variability in response to insulin 
and thus prediction errors were higher than expected, likely due to the recent insult of cardiac surgery 
or a major cardiac event, and their immediate recovery. STAR effectively managed this variability 
with no hypoglycemia. Improved stochastic models will be used to prospectively test these outcomes 
in further ongoing clinical pilot trials in this and other units. 
 
  
1. INTRODUCTION 
 
Critically ill patients often present stress-induced hyperglycemia due to significant stress-induced in-
sulin resistance. Hyperglycemia worsens outcomes and increases mortality [1-4]. Effective glycemic 
control should reduce blood glucose (BG) levels, reduce variability and account for inter- and intra- 
patient variability and evolving physiological patient condition [5-7]. Some studies have shown that 
tight glycemic control (TGC) can reduce mortality up to 45% and significantly reduce negative out-
comes linked to hyperglycemia [8-10]. However, achieving these outcomes has been difficult to re-
produce [11-13] in the variable and dynamic critical care patient. 
 
Hypoglycemia is a major risk associated with TGC [3, 14, 15]. Limiting hypoglycemia and ensuring 
safety is critical for any TGC protocol. However, its occurrence is exacerbated by patient variability 
and only one study reduced hypoglycemia with TGC [10]. BG measurement frequency also varies 
significantly across reported studies, from 1 to 4 hours, where longer intervals can lead to greater gly-
cemic variability and hypoglycemia [16, 17]. Model-based controllers using computer models of pa-
tient physiology can enable a TGC protocol to capture the patient-specific response to insulin and nu-
trition inputs and account for patient-specific dynamics to optimize interventions and BG levels [7, 17-
20]. 
 
The STAR (Stochastic TARgeted) model-based controller presented in this paper is a framework that 
enables adaptive, patient-specific TGC. The STAR protocol directly accounts for evolving physiologi-
cal patient condition and intra-patient variability by identifying insulin sensitivity (SI) changes at each 
intervention and using a stochastic model of its future potential variability [6, 7] to optimize control 
and maximize safety. Because STAR is a model-based approach it can be customized for clinically 
specified glycemic targets, control approaches (e.g. insulin only, insulin and nutrition, etc.) and clini-
cal resources (measurement frequency). This paper presents a STAR protocol modulating insulin infu-
sions only towards a target glycemia of 125 mg/dL per clinical practice in the trial ICU, and the initial 
pilot trial results of the protocol. 
This pilot trial also tested the ability to adapt the model-based STAR TGC framework from its devel-
opment environment at Christchurch Hospital in New Zealand to a completely separate institute in 
Liege, Belgium. Specifically, the following areas of control design and performance were explored: 
 
• Control of BG in post-surgical patients by modulating insulin infusions only. This is a depar-
ture from previous use of this model in a heterogeneous ICU cohort, using primarily the bolus 
route to introduce exogenous insulin, while also explicitly modulating nutritional inputs for 
glycemic control. 
• Real-time model prediction performance in clinical trial in an ICU with different clinical prac-
tices and patient populations from Christchurch, NZ. 
• Suitability of the applied stochastic model to this Belgian group of patients. In particular, were 
the stochastic models generated from a heterogeneous ICU population over all patient days 
applicable, or were more specialized stochastic models required? 
 
  
2. METHOD 
 
2.1. STAR-Liege Protocol 
 
The STAR-Liege protocol presented is customized in glycemic target (125 mg/dL) and control inter-
ventions (insulin-only via infusions) to match clinical standards at CHU of Liege (Belgium). If neces-
sary, it raises nutrition rates to avoid hypoglycemia when no exogenous insulin is being given. The 
time interval between BG measurements is also determined by the protocol, with intervals of 1 and 2 
hours for this pilot study. The step-by-step description of this protocol is illustrated in Figure 1 and the 
insulin rate is calculated as follows: 
1. Previous and current blood glucose measurements are used to identify a patient-specific cur-
rent SI parameter value for the prior time interval [21]. This step accounts for inter-patient 
variability [17, 22, 23].  
2. For a given patient, insulin sensitivity is quite variable over time (even hour to hour variation 
of SI parameter value can be important). The stochastic model [6, 7] provides a distribution of 
possible SI parameter values for the next 1-2 hours and accounts for intra-patient variability. 
This New Zealand patient-based stochastic model was assumed to be broadly applicable to 
Belgian patients as hour-to-hour insulin sensitivity variability in retrospective comparison is 
similar [5].  
3. The target BG value for the next 1-2 hour interval is defined from the current BG levels 
(𝐵𝐺𝑛𝑛𝑛) by:  
𝐵𝐺𝑡𝑎𝑟𝑔𝑒𝑡,t+1h/+2h = max (0.85 ∗ 𝐵𝐺𝑛𝑛𝑛 , 125) 
where reductions of 15% per interval are targeted until the target of 125 mg/dL is achieved. 
4. The insulin rate required to achieve this BG target is computed with a bisection method using 
a clinically validated insulin-glucose system model [23-25] and the median (50th percentile) 
expected SI value over the next 1-2 hours, obtained from the stochastic model distribution [6, 
7]. Note that the median value is the same as the current SI (no change) at all levels [6, 7]. 
5. Once an insulin intervention is found, the BG outcome predictions are calculated for the 5th, 
25th, 75th and 95th percentile SI values from the stochastic model in Step 2 over the next 1-2 
hours. These results show the possible BG spread due to intra-patient variability typically ob-
served in critical care patients. 
6. The predicted outcome BG range in Step 5 is checked to ensure the lowest possible BG (5th 
percentile) is not < 72 mg/dL, ensuring a guaranteed maximum risk of 5% for BG < 72 
mg/dL, for safety from moderate (< 60 mg/dL) or severe (< 40 mg/dL) hypoglycemia. 
7. If the lowest BG is < 72 mg/dL, the insulin rate is reduced to ensure the maximum risk of BG 
< 72 mg/dL remains 5%, which effectively raises the target BG level defined in Step 3, so that 
the 5th percentile outcome is equal to 72 mg/dL. If this step is necessary it effectively raises 
the BG target in recognition that the original target cannot be safely attained due to the insulin 
resistance of the patient requiring large insulin doses making the stochastic (5th – 95th percen-
tile) band too wide. 
These steps define the STAR-Liege protocol used in this research and are illustrated in Figure 1. The 
overall, basic model-based STAR framework was adapted to local clinical conditions in glycemic 
targets (Step 3), interventions (Step 4) and/or limits (Step 6). 
 
A maximum insulin rate of 6 U/h is prescribed for safety and to avoid insulin saturation effects [26, 
27]. Similarly, the insulin rate rise per intervention is limited to +1U/h if the previous insulin rate is < 
1U/h and to +2U/h otherwise to avoid over responding to sudden changes or larger sensor errors. To 
reduce nursing staff workload associated with making small and frequent changes in insulin rates and 
thus improve clinical implementation, insulin rates were limited to specific values of (0.0, 0.5, 1.0, 1.3, 
1.5, 1.8, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0) U/hour. 
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Figure 1 – STAR-Liege protocol. Initial situation: BG measurement. Step 1: SI parameter value calculation and pa-
tient-specific model adaptation to inter-patient variability (Integral Fitting Method [21]). Step 2: Distribution of pos-
sible SI parameter values (Stochastic Model [6, 7]). Step 3: Definition of the target BG value for the next 1-2 hours. 
Step 4: Insulin rate calculation to meet the target with same SI (Bisection Method). Step 5: Stochastic model analysis 
of intra-patient variability and range of glycemic outcomes. Step 6: Hypoglycemia prevention for 5th percentile out-
come, BG5% ≥ 72 mg/dL. Step 7: Insulin rate adjustment (if necessary) to ensure BG5% ≥ 72 mg/dL. 
 
A desired 6.25 g/hour default enteral nutrition rate is requested, based on [28], but nutrition admin-
istration is left to the attending clinician. There is typically no parenteral nutrition, unless clinically 
specified otherwise. To prevent unintended hypoglycemia, enteral and parenteral nutrition rates can be 
increased by 10% when BG ≤ 108 mg/dL and no insulin has been given or recommended. In this case, 
the nutrition rates are increased only until the next blood glucose measurement, but can be maintained 
if required. 
 
The protocol specifies hourly BG measurement, but measurement frequency is decreased by going to a 
120-minute interval when the patient is glycemically stable. Stability is defined here as occurring 
when the current and last three BG measurements are between 90 mg/dl and 139.5 mg/dl. These rela-
tively short 1-2 hour intervals are used to avoid drift during longer intervals [16]. They also match 
those used in all or part of other protocols (e.g. [10, 11, 19]), as well as ensuring safety in this proof-
of-concept pilot trial. 
 2.2. Pilot Trial and Patients 
 
The STAR-Liege protocol was tested in July 2010 at the Centre Hospitalier Universitaire (CHU) in 
Liège, Belgium. The pilot trial was 24 hours long and included 9 primarily cardiovascular or cardiac 
surgery (7) patients from the hospital’s intensive care units, 3 patients (Patients 2, 3 and 6) were in the 
first 24 hours post-surgery. Patients were recruited when they had initial blood glucose levels > 145 
mg/dL. Table 1 shows the patient details. Ethical consent was granted by the Comité d’éthique hos-
pitalo-facultaire de l’Universitaire de Liège (B70720108843) for the performance of this trial and the 
audit, analysis and publication of these data. 
 
For each patient, the trial started with a BG measurement made by nursing staff. BG measurements 
were made using Accu-Chek Inform (Roche Diagnostics, Mannheim, Germany) glucometers. The 
protocol then calculated a new insulin infusion rate, which was then given by the nurse. The time in-
terval until the next BG measurement is also specified. This clinical procedure is shown in Figure 2. 
 
 
Figure 2 - Pilot trial clinical implementation. The dashed line shows the boundary between the computerised protocol 
elements (right) and the measurements or clinical actions (left). 
 
 
Patient bedside Protocol (on computer) 
BG measurement by nurse 
 
Infusion data: insulin and 
nutrition rates (pumps) 
New insulin and nutrition rates 
 
Time interval until next BG measurement 
 
 
 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 
G
en
er
al
 in
fo
rm
at
io
n 
Date of birth 30/01/1931 8/03/1932 12/06/1941 13/04/1931 11/07/1928 19/12/1938 13/05/1949 14/03/1936 7/12/1965 
Sex M F M M F F M M M 
Diagnosis Hypercapnia,  Coma  
Aortic valve re-
placement 
Triple coronary 
artery bypass 
surgery 
Cerebral aneurysm Gastro-Intestinal surgery Post-RVA 
Myocardial infrac-
tion + Cardiac 
arrest + ECMO 
Mitral valve re-
placement Post-RVA 
Diabetic No No 
Yes (type II) 
Non insulin-
dependent 
No Yes (type II) Insulin-dependent 
Yes (type II) 
Non insulin-
dependent 
Yes (type II) 
Non insulin-
dependent 
No No 
Post-surgical days in ICU 5 1 1 4 14 0 16 3 7 
C
on
tr
ol
 d
et
ai
ls 
Initial BG (mg/dL) 199 159 147 166 150 152 168 184 160 
Did nurses override  
recommended insulin 
rate? 
Yes, 2 times Yes, 2 times Yes, 1 time No No No No Yes, 4 times No 
Meals  / / Pudding : 1 spoon-ful / / Pudding / / / 
Additional drugs? 4 mg of MethylPrednisone / / / / / / Antibiotic / 
Vomiting? No No No No 
Yes, after 1530 
minutes (trial 
stopped for 4 
hours) 
No No 
Yes, after 810 
minutes (trial 
stopped for 1 hour)  
No 
Notes Hypoxic episode during trial / / / / / / / / 
Table 1 - Clinical details for recruited patients, where RVA = Right Ventricular Aneurysm  
  
2.3. Stochastic Models 
 
The goal of a stochastic model is to describe the hourly variations of the insulin sensitivity. A stochas-
tic model is based on clinically observed insulin sensitivity variations in ICU population data (for 
more information, refer to appendix). These clinical data can come from a specific type of patients and 
can be selected in function of the patient days of stay. 
 
The stochastic model initially used in the trial was that of Lin et al. [6, 7] based on all types of patients 
included in the SPRINT1 glucose control study and all patient days of stay. However, post-operative 
cardiac surgery patients in the first few post-operative days have recently been found, based on the 
results of this pilot study, to potentially be as much as two times more variable in their insulin sensitiv-
ity than this broader cohort [unpublished]. Hence, new stochastic models using data from cardiac-
surgery patients were generated to better account for this variability and for post-trial assessment of its 
impact on the clinical results. 
 
Eight new stochastic models are defined, as shown in Table 2. Each new stochastic model is based on 
different clinical data sets characterized by three features:  
1. the study group: clinical data can come from patients included in the SPRINT study or in the 
Glucontrol study 2 (or both); 
2. the type of patients: clinical data can come from all patients included in the previous selected 
study(ies), or from a specific type of patients (cardiac-surgery or not cardiac surgery patients); 
3. the days of stay: clinical data can come from all days or specific day(s) of patient’s ICU stay. 
                                                     
1 SPRINT refers to specialized relative insulin nutrition tables. It’s a model-based clinical protocol for glycemic 
control that modulates both insulin and nutrition inputs. 29. Chase, J.G., G. Shaw, A. Le Compte, T. Lonergan, 
M. Willacy, X.W. Wong, J. Lin, T. Lotz, D. Lee, and C. Hann, Implementation and evaluation of the SPRINT 
protocol for tight glycaemic control in critically ill patients: a clinical practice change. Crit Care, 2008. 12(2): 
p. R49. 
2 Glucontrol refers to a prospective randomized controlled trial that compares the effects on ICU mortality of 
intensive insulin therapy (IIT) with an intermediate glucose control. 11. Preiser, J.C., P. Devos, S. Ruiz-
Santana, C. Melot, D. Annane, J. Groeneveld, G. Iapichino, X. Leverve, G. Nitenberg, P. Singer, J. Wernerman, 
M. Joannidis, A. Stecher, and R. Chiolero, A prospective randomised multi-centre controlled trial on tight 
glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. Intensive Care 
Med, 2009. 35(10): p. 1738-48. 
Models 1 to 6 use data from specific days and cohorts to better match the enhanced variability ob-
served clinically in these specific pilot trial cardiac-surgery patients. Models 7 and 8 are based on a 
parameter modification in the generation of the original stochastic model [30]. More precisely, the 
variance of each data point of the hourly changes in 𝑆𝐼 distribution (each couple (𝑆𝐼,𝑛 = 𝑥𝑖 , 𝑆𝐼,𝑛+1 =
𝑦𝑖)) is modified compared with the original model. Patient data from the SPRINT and Glucontrol da-
tabases were used to create these new models. SPRINT patients were treated at Christchurch hospital 
in New Zealand between August 2005 and April 2007 [29] and Glucontrol was a multi-center study 
with data from 21 participating ICUs in 7 countries across Europe during the period November 2004 – 
May 2006 [11]. However, only Glucontrol data from the CHU of Liege site was used here. 
Stochastic model Study group Type of patients Patient days of stay N 
Original (used in pilot trials [6, 7]) SPRINT All patients All days of stay / 
Model 1 SPRINT Cardiac surgery patients Day 1 1361 
Model 2 SPRINT Cardiac surgery patients Day 2 701 
Model 3 SPRINT Non- cardiac surgery patients Day 1 6442 
Model 4 Glucontrol All patients Day 1 991 
Model 5 (Models 1 + 4) SPRINT Glucontrol 
Cardiac surgery patients 
All patients Day 1 2352 
Model 6 (Models 1 + 2) SPRINT Cardiac surgery patients Days 1 and 2 2062 
Model 7 (original model with 1.5x variance modifier)  SPRINT All patients All days of stay / 
Model 8 (original model with 1.5x variance modifier) SPRINT All patients All days of stay / 
Table 2 - New stochastic model definitions for assessing variability and results observed in pilot clinical trial (N refers 
to the number of hours used to create the stochastic model) 
 
These models are assessed using the clinical data from this trial. Forecasting performance is assessed 
by the number of clinical results falling in an interquartile range (denoted as IQR, 50% confidence 
interval band) and 90% confidence interval band (expect ~50% and ~90%). The different stochastic 
models are also assessed in clinically validated virtual trial re-simulations [23] of the trial to determine 
the potential impact on interventions given and glycemic outcomes.  
  
3. RESULTS 
 
3.1. Clinical Trial Results - Blood Glucose Control Performance 
 
Clinical results are summarized by whole cohort and per-patient statistics in Table 3. There were 205 
BG measurements taken during 215 hours of control. Hence, primarily 1-hour measurements were 
specified by the STAR-Liege protocol. This result can also be seen in the individual patient results in 
Table 4. Overall, these results indicate that patients were particularly resistant to glycemic stability. 
This outcome is likely due, in part, to the fact that they were recently out of cardiac surgery and thus 
more variable in their insulin sensitivity. 
 
Whole cohort statistics Per-patient statistics (presented as median [IQR]) 
Number of patients: 9 Initial BG (mg/dL): 160.0 [151.5 - 172.0] 
Total hours: 215 hours Hours of control: 24.0 [23.0 - 24.3] 
Number of BG measurements: 205 Number of BG measurements: 24.0 [22.0 - 24.0] 
BG median [IQR] (mg/dL): 136.0 [122.5 - 158.0] BG median (mg/dL) 138.5 [130.6 - 146.0] 
% BG within 80-110 mg/dL 8.8 Median %BG within 80-110 mg/dL [IQR]: 8.3 [4.2 – 9.9] 
% BG within 110-140 mg/dL 45.4 Median %BG within 110-140 mg/dL [IQR]: 50.0 [31.2 - 54.2] 
% BG within 140-180 mg/dL 37.1 Median %BG within 140-180 mg/dL [IQR]: 40.9 [28.4 – 41.7] 
% BG ≥ 180 mg/dL 8.3 Median %BG ≥ 180 mg/dL [IQR]: 8.3 [0.0 – 17.0] 
% BG < 80 mg/dL 0.5 Time to < 125 mg/dL (hours): 4.0 [2.1 – 5.0] 
% BG < 72 mg/dL 0.5 % patients to < 125 mg/dL: 100 
% BG < 40 mg/dL 0.0 Time to < 140 mg/dL (hours): 2.1 [2.0 – 4.0] 
Number of patients < 40 mg/dL 0 % patients to < 140 mg/dL: 100 
Median insulin rate [IQR] (U/hour): 1.5 [0.5 – 3.4] Median insulin rate [IQR] (U/hour): 1.3 [0.9 – 2.4] 
  Max insulin rate [IQR] (U/hour): 6.0 [4.7 – 6.0] 
Median glucose rate [IQR] (g/hour): 7.4 [2.0 – 11.2] Median glucose rate [IQR] (g/hour): 4.2 [2.0 – 11.1] 
Table 3 – Clinical results for the whole cohort (left column) and per-patient statistics (right column) for glucose con-
trol performance and interventions (insulin, glucose administration) given. 
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1 24 22 199 134.0 [121.0 - 167.0] 9.1 50.0 18.2 18.2 4.5 4.5 0 63 
1.3 
[0.7 - 2.0] 6.0 
11.0 
[11.0 - 11.0] 
2 23 19 159 115.0 [102.3 - 130.0] 31.6 52.6 15.8 0.0 0.0 0.0 0 82 
0.2 
[0.0 - 1.0] 3.8 
2.0 
[2.0 - 2.0] 
3 23 22 147 128.0 [123.0 - 147.0] 4.5 63.6 31.8 0.0 0.0 0.0 0 105 
0.8 
[0.0 - 1.6] 4.0 
2.0 
[2.0 - 2.0] 
4 23 24 166 145.5 [124.0 - 167.5] 12.5 29.2 41.7 16.7 0.0 0.0 0 98 
2.0 
[0.8 - 4.0] 6.0 
10.5 
[9.5 - 10.5] 
5 26 24 150 138.5 [129.5 - 150.0] 0.0 54.2 41.7 4.2 0.0 0.0 0 110 
1.0 
[0.0 - 2.0] 5.0 
3.7 
[1.4 - 7.4] 
6 24 24 152 149.0 [133.0 - 159.5] 4.2 29.2 58.3 8.3 0.0 0.0 0 109 
1.0 
[0.0 - 4.0] 5.8 
2.0 
[2.0 - 2.0] 
7 23 24 168 140.5 [127.0 - 165.0] 4.2 45.8 41.7 8.3 0.0 0.0 0 108 
3.8 
[2.8 - 5.7] 6.0 
11.2 
[11.2 - 11.2] 
8 24 22 184 147.5 [130.0 - 161.0] 9.1 31.8 40.9 18.2 0.0 0.0 0 105 
1.8 
[0.1 - 5.8] 6.0 
4.2 
[4.2 - 14.9] 
9 25 24 160 131.5 [120.5 - 152.0] 8.3 54.2 37.5 0.0 0.0 0.0 0 108 
3.5 
[1.9 - 4.8] 6.0 
17.6 
[12.0 - 17.6] 
Table 4 - Clinical results for each individual patient 
 
BG median values in Tables 3 and 4 are higher than the BG target of 125 mg/dL, except for Patient 2. 
BG levels are relatively distributed, as evidenced by the IQR range (75th – 25th percentile value) of 
35.5 mg/dL in Table 3 for the cohort, and the 25%-75% confidence interval across patients in Figure 
3. Note that the slope of the per-patient BG cumulative distribution function (CDF) median is slightly 
steeper at low BG, so that BG levels are skewed toward higher values as expected with this stochastic 
model driven approach, as well as for short pilot trial with high initial BG values.  
 
 
Figure 3 - Median, 25-75% and 5-95% intervals of per-patient BG CDFs defined on whole cohort, where the solid line 
shows the target BG = 125 mg/dL. 
 
Table 3 shows that 45.4% of BG measurements are between 110 and 140 mg/dL and the control is 
tight in this band, as illustrated by the steep slope of BG CDF for the whole cohort in Figure 4 and 
similar per-patient CDFs in Figure 3. A total of 70% of measurements are between 110 and 160 
mg/dL, which is largely due to the short length of trial where 8-17 % of total trial time was spent re-
ducing initial BG levels to 140 mg/dL (Table 3). Thus, the pilot trial length wasn’t sufficient to 
achieve consistently high percentages of BG levels in a tight band around the target. In addition, pa-
tient variability played a role in the further time spent with BG > 140 mg/dL.  
 
Importantly for safety, Tables 3 and 4 show that there was no severe hypoglycemic measurement (BG 
< 40 mg/dL). The minimum value reached was 63 mg/dL (Patient 1). Hence, the STAR approach re-
duced BG levels safely without hypoglycemia. More specifically, STAR guarantees a maximum risk 
of 5% for BG < 72 mg/dL by design, where these initial results show 1 out of 205 measurements 
(0.5%). 
 
Finally, nurses only overrode 9 (4.4 %) of the 205 interventions recommended, usually to give a 
slightly lower insulin dose, indicating good overall compliance. 
 
Figure 4 - BG, insulin rate and dextrose rate CDF’s defined for the whole cohort 
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The CDF in Figure 4 shows that no insulin is given in 25% of controller interventions, and that insulin 
rates varied over the full range allowed. Only 25% of insulin rates are higher than 3.2 U/hour, but 
more than half of the patients received the maximum allowable insulin rate of 6 U/hour at least once 
during the 24-hour trial (Patients 1, 4, 7, 8 and 9, Table 4). These results indicate the significant intra- 
and inter- patient variability in insulin sensitivity encountered, which was initially unexpected from 
the cohort-based stochastic model. They might also be expected in part, as 3 of the patients were in an 
acute post-surgical (first day) phase (Table 1).They also indicate the adaptability of the model-based 
TGC protocol in responding to these changes. 
 
Similarly, 25% of clinically specified exogenous glucose rates are between 2.0 and 7.4 g/hour. More 
than a quarter of dextrose rates are equal to 2.0 g/hour and approximately 40% of dextrose rates are 
between 10.0 and 12.0 g/hour. These results indicate patients were fed very differently, due to specific 
clinical orders given. Patient 8 in particular received highly variable nutrition rates during the trial for 
(unspecified) clinical reasons, which would have been a further factor in the variable insulin rates ob-
served as the model-based controller responded to these changes.  
 
3.2. Clinical Results - Model Control Performance 
 
Control performance relies directly on the model’s prediction ability. Table 5 shows that the average 
prediction error is 13.9 mg/dl (10.5%). To reduce this error, the system model has to be improved by 
revisiting the fundamental model structure or the population parameters. However, forecasts within 
stochastically defined prediction ranges (5%-95% and 25%-75%) are lower than expected (71.6% and 
26.1%, instead of 90% and 50%, respectively). This result shows that this group of patients had signif-
icantly increased variability in insulin sensitivity compared to the stochastic model used to guide con-
trol [7], which was also similar to a prior analysis over 200 CHU patients over all days of stay [5]. 
Therefore, to make improvements about forecasting, the original stochastic model needs to be more 
specific. 
 
 Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Average 
Median prediction error (mg/dL) 13.9 13.2 12.9 18.0 15.3 17.3 11.6 11.8 10.9 13.9 
25th percentile error (mg/dL) 6.8 5.0 4.2 9.4 5.7 10.4 6.7 5.5 4.0 6.5 
75th percentile error (mg/dL) 39.1 25.9 33.7 28.1 41.5 31.0 17.1 22.5 16.0 28.3 
Median prediction error (%) 12.5 11.7 10.5 12.7 11.5 12.9 6.8 8.5 7.9 10.5 
25th percentile error (%) 5.0 4.8 3.4 7.0 4.2 6.7 5.3 3.5 3.3 4.8 
75th percentile error (%) 27.9 21.9 23.5 17.4 29.1 18.3 14.2 17.4 12.5 20.2 
Total Forecasts 20 16 20 23 22 22 22 21 25 21.2 
Predictions within 90% confi-
dence interval (%) 65 44 65 74 64 68 91 86 88 71.6 
Predictions within IQR (%) 35 19 20 22 23 14 23 29 52 26.1 
Table 5 - Statistics on model prediction performance 
 
3.3. Stochastic Model Assessment – Virtual Trial Results 
 
This section analyses the changes due to the incorporation of different stochastic models representing 
cardiac-surgery post-operative patients (Table 2). Virtual trial [16, 17, 23] was performed using the 
eight new stochastic models of Table 2 to better assess the increased variability in insulin sensitivity 
observed. 
 
The original stochastic model, based on all SPRINT patients over their entire ICU stay and used dur-
ing clinical pilot trial, had only 71.6% of forecasts within 5%-95% and 26.1% within 25%-75% (Table 
5). Among the proposed models in Table 2, Model 5 yielded 85.1% and 43.8%, respectively. These 
values are acceptable [7] given the relatively low number (205) of predictions. Therefore, this new 
model generated solely from SPRINT and Glucontrol cardiac-surgery patient data on only day 1 of 
their stay, better accounts for the variability in insulin sensitivity observed in this trial with similar 
patients. Models 1, 2, 4 and 6 are similar in results, and, notably use only the first 1-2 days of stay for 
cardiovascular surgery or cardiac care patients, similar to the cohort in this ICU. 
 
  
Comparison of the model control performance for these new stochastic models is shown in Table 6. 
 
 Original Model Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 
Median prediction error (mg/dL) 13.9 15.8 13.9 13.9 13.3 14.8 14.4 13.9 13.9 
25th percentile error (mg/dL) 6.5 7.9 6.7 6.1 6.3 6.7 7.0 6.3 6.3 
75th percentile error (mg/dL) 28.3 30.1 27.7 27.9 28.8 29.2 29.2 28.3 28.3 
Median prediction error (%) 10.5 11.6 10.5 10.4 10.2 11.2 11.1 10.2 10.2 
25th percentile error (%) 4.8 5.8 4.8 4.5 4.6 5.0 4.9 4.7 4.7 
75th percentile error (%) 20.2 20.7 20.1 20.3 20.9 20.6 20.3 20.3 20.3 
Predictions within 90% confi-
dence interval (%) 71.6 84.3 78.0 79.3 82.5 85.1 83.1 67.4 69.5 
Predictions within IQR (%) 26.1 46.5 41.2 40.0 44.2 43.8 41.3 26.9 27.4 
Table 6 - Model control performance for new stochastic models 
 
The potential impact of control performance of using a more specialized stochastic model was investi-
gated in virtual trial re-simulations of the clinical trial. Tables 7 and 8 present whole cohort and per-
patient statistics of the clinical and (re-simulated) virtual trial, respectively. The first column refers to 
the actual clinical results. The second and third columns refer to virtual trial using the original stochas-
tic model and the new Model 5, respectively. Differences, particularly in columns 2 and 3, assess pos-
sible outcomes from using a stochastic model more specific to this patient group. 
 
 Clinical data 
Clinical trial 
re-simulated 
as per-protocol 
Simulations with 
new stochastic model 
(Model 5) 
Number of patients: 9 9 9 
Total hours: 215 hours 208 hours 208 hours 
Number of BG measurements: 205 198 198 
BG median [IQR] (mg/dL): 136.0 [122.5 - 158.0] 135.8 [122.9 - 153.3] 131.7 [118.8 - 150.8] 
% BG within 80-110 mg/dL 8.8 7.1 10.6 
% BG within 110-140 mg/dL 45.4 49.5 48.0 
% BG within 140-180 mg/dL 37.1 36.4 32.8 
% BG ≥ 180 mg/dL 8.3 6.6 7.1 
% BG < 80 mg/dL 0.5 0.5 1.5 
% BG < 72 mg/dL 0.5 0.0 1.0 
% BG < 40 mg/dL 0.0 0.0 0.0 
Number of patients < 40 mg/dL 0 0 0 
Median insulin rate [IQR] (U/hour): 1.5 [0.5 - 3.4] 1.5 [0.5 - 3.9] 2.0 [0.8 - 4.7] 
Median glucose rate [IQR] (g/hour): 7.4 [2.0 - 11.2] 7.4 [2.0 - 11.2] 7.4 [2.0 - 11.2] 
Table 7 - Re-run virtual trial analysis results: whole cohort statistics 
  
 Clinical data 
Clinical trial 
re-simulated 
as per protocol 
Simulations with 
new stochastic model 
(Model 5) 
Initial BG (mg/dL): 160.0 [151.5 - 172.0] 160.0 [151.5 - 172.0] 160.0 [151.5 - 172.0] 
Hours of control: 24.0 [23.0 - 24.3] 23.0 [22.0 - 23.5] 23.0 [22.0 - 23.5] 
Number of BG measurements: 24.0 [22.0 - 24.0] 23.0 [21.0 - 23.3] 23.0 [21.0 - 23.3] 
BG median (mg/dL) 138.5 [130.6 - 146.0] 136.3 [130.2 - 142.8] 131.4 [126.9 - 141.0] 
Median %BG within 80-110 mg/dL [IQR]: 8.3 [4.2 – 9.9] 4.8 [3.3 - 8.9] 13.0 [3.6 - 14.9] 
Median %BG within 110-140 mg/dL [IQR]: 50.0 [31.2 – 54.2] 54.2 [34.8 - 57.1] 45.8 [34.8 - 54.8] 
Median %BG within 140-180 mg/dL [IQR]: 40.9 [28.4 – 41.7] 37.5 [28.6 – 44.1] 33.3 [22.3 – 39.0] 
Median %BG ≥ 180 mg/dL [IQR]: 8.3 [0.0 - 17] 4.3 [0.0 - 13.4] 4.3 [0.0 - 13.4] 
Time to < 125 mg/dL (hours): 4.0 [2.1 - 5.0] 4.0 [3.8 - 6.4] 4.0 [3.8 - 6.1] 
% patients to < 125 mg/dL: 100 100 100 
Time to < 140 mg/dL (hours): 2.1 [2.0 - 4.0] 3.0 [2.0 - 4.3] 3.0 [2.0 - 4.3] 
% patients to < 140 mg/dL: 100 100 100 
Median insulin rate [IQR] (U/hr): 1.3 [0.9 - 2.4] 1.4 [1.0 - 3.4] 1.7 [1.0 - 4.3] 
Max insulin rate [IQR] (U/hr): 6.0 [4.7 - 6.0] 6.0 [5.1 - 6.0] 6.0 [5.8 - 6.0] 
Median glucose rate [IQR] (g/hour): 4.2 [2.0 - 11.1] 4.2 [2.0 - 11.1] 4.2 [2.0 - 11.1] 
Table 8 - Re-run virtual trial analysis results: per-patient statistics (presented as median [IQR]) 
 
Differences between the clinical data and simulations using the original stochastic model arise from 
different nursing interventions and ability of the simulation environment to replicate the clinical trial 
[23]. During the pilot trial, slightly less insulin than specified by the controller was administered to 
patients in some cases if the nurses chose to override the recommendations (9 of 205, 4.4%), which 
explains the slightly higher BG levels for the clinical data. The difference in trial length and number of 
BG measurements in the simulated trial can be attributed to delays in BG measurements in the clinical 
environment and subsequent rounding of intervention times (where the simulated controller would 
take measurements on the hour). However, with respect to glycemic outcome, these differences are not 
clinically significant. 
  
 Total hours Number of measurements 
Patient Clinical data Clinical trial re-simulated as per-protocol Clinical data 
Clinical trial re-simulated as 
per-protocol 
1 24 23 22 21 
2 23 22 19 18 
3 23 22 22 21 
4 23 22 24 23 
5 26 26 24 24 
6 24 23 24 23 
7 23 22 24 23 
8 24 23 22 21 
9 25 25 24 24 
Table 9 - Comparison between clinical data and clinical virtual trials re-simulated as per-protocol in terms of number 
of measurements and trial length 
 
It is observed in Tables 7-9 that there is no real difference in measurement frequency using the new 
Model 5 stochastic model. It is also seen that patients received more insulin (~ 30%) in re-simulated 
trial, especially with Model 5. This result explains the lower BG levels associated with Model 5 in 
Table 8 and in the BG CDFs shifting to slightly lower BG values in Figure 5 with a steeper slope at 
intermediate values. Nutrition rates are the same as they were kept at the clinically specified levels. 
 
 
Figure 5 – Comparison of CDF's defined on whole cohort between clinical data and virtual trial. From top to bottom: 
BG, insulin rate and dextrose rate CDF’s 
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Clinical Data
Clinical trials re-simulated as per-protocol
Simulations with new stochastic model (Model 5)
 Table 10 shows the p-values comparing the CDFs in Figure 5. The clinical data to STAR rerun (col-
umn 1) shows the impact of timing or delayed/missed clinical measurements, as well as any rounding 
of the insulin interventions given. The second column indicates that using a more relevant stochastic 
model (Model 5) would have yielded a different set of insulin interventions, as seen in Table 8, with 
lesser impact on BG likely due to trial length. The p –value of 0.91 between clinical data and re-
simulation results results from small increases in nutrition in re-simulations, based on increases in 
nutrition rates at lower BG values with no insulin being given, and is thus not 1.0. 
 
P-values Clinical Data/STAR rerun Clinical Data/Model 5 
BG 0.78 0.12 
Insulin rate 0.13 0.01 
Nutrition rate 0.91 0.91 
Table 10 - p-values using Wilcoxon rank sum test for equal medians. The p-value is the probability of observing a 
difference between the two data set medians as large as the difference observed here, or larger, assuming the hypothe-
sis that the medians are equal. 
  
4. DISCUSSION 
 
This proof-of-concept trial is the first attempt to use the STAR approach outside the neonatal ICU 
(NICU) [25] and initial STAR trials ongoing in Christchurch ICU. One important result is that no se-
vere hypoglycemia (BG < 40 mg/dL) occurred during this 24-hour clinical pilot trial. The minimum 
BG recorded was 63 mg/dL for Patient 1, with the next lowest at 82 mg/dL for Patient 2. Hence, there 
was no apparent risk of hypoglycemia, despite the unexpected high metabolic variability in SI ob-
served. 
 
The control was generally consistent across different, highly variable patients, as seen in Figure 3. 
However, the time spent at the 125 mg/dL target was relatively low due primarily to patient variabil-
ity, high initial BG levels, and the short 24-hour total trial length. The fact that relatively long times in 
the desired glycemic bands (110-140 mg/dL in particular) were achieved supports the overall efficacy 
of this approach.  
 
During the pilot trial, several patients displayed relatively large variability in insulin sensitivity, as 
shown by example for Patient 3 in Figure 6. This variability exceeded the predictions of the cohort-
based stochastic model and made accurate model-based forecasting, prediction and TGC more diffi-
cult. As a result, forecasts within prediction ranges were lower than expected (Table 5). New stochas-
tic models using clinical data specific to cardiac-surgery patients and for specific days post-surgery 
were much more effective in capturing this variability. It should also be noted that Patient 3 was im-
mediate post-surgery, and this greater variability should perhaps be expected based on the re-analysis 
done with modified stochastic models. The improved forecasting in Table 6 for models using only 1-2 
days of stay indicates that the greater variability seen here may be reflective of patients early in their 
stay being more variable. Earlier analyses [5] showed similar variability for a similar cohort over all 
days, but did not examine specific patients or days of stay. Equally, these 9 patients may simply have 
been more variable. 
 
 
Figure 6 - STAR trial progression for Patient 3, BG (top) and model-based SI (bottom). The SI variation observed is 
very large, particularly over hours 0-12. 
 
The main goal of this pilot trial was to assess performance, safety and implementation issues. In par-
ticular, several features were adapted for clinical implementation and to reduce nursing effort, which 
was higher than desired. Three-hour measurement periods would be desirable to further reduce nursing 
staff effort. However, as patients were not glycemically stable in this pilot trial such an improvement 
would not have been effective here. Longer trials over more patients would see improvements if varia-
bility declined over time or if patients were less variable than the small subset in this pilot trial.  
 
Equally, longer intervals can be implemented using improved stochastic models and accepting a lower 
level of control than targeted in this study. In particular, stochastic bounds can be used to maximize 
the likelihood of BG in a desired range, as opposed to a specific target, as has been done in NICU 
STAR studies [25]. This approach and other changes will be implemented and tested going forward. 
 
In addition, when insulin infusions are used with hourly measurement, a measurable fraction of the 
administered insulin has no time to act before the end of the hour, and insulin “cycling” may occur. 
Insulin “cycling” is defined here as periodic insulin rate evolution characterized by a progressive in-
crease followed by a sudden decrease. This behavior is illustrated by Patient 6 in Figure 7. These cy-
cles occur in part due to clinically imposed limits in increasing insulin infusion rates (for safety) in 
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response to increasing BG. However, because a given infusion rate’s full effect is not seen before the 
end of one hour (~55%) the controller using a model for hour-to-hour control may underestimate its 
effect and thus increase the infusion rate further. This effect is exacerbated at the relatively low (or 
zero) insulin infusion rates seen in this study. The presence of higher rates of insulin infusion may 
allow the model to make a more accurate estimation of patient state by reducing the impact of endoge-
nous insulin production, for which the model must assume a population constant [23] as it is currently 
not measurable in clinical real-time. Hence, longer time intervals might be better when using infusions 
of insulin compared to bolus administration in SPRINT [16].  
 
 
Figure 7 - STAR trial progression for Patient 6: evolution of insulin rates with a constant nutritional administration 
rates 
 
Protocol application in the clinical environment was not perfect. Some situations were not managed 
automatically by the controller, such as when the patient vomited or was given meals. Such events 
were managed on a case-by-case basis by stopping the dextrose input to the controller, or assuming an 
equivalent dextrose infusion, for vomiting and meals, respectively. These events are important for 
TGC because BG levels are directly linked to carbohydrate administration and appearance. The result-
ing estimations made on how much carbohydrate might appear, and at what time, also affected the 
quality of control obtained. These issues affected Patients 3, 5, 6 and 8 on one occasion each. Future 
work will involve revising the control scheme to take better account of such possible scenarios to im-
prove the clinical implementation and make it more autonomous. 
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5. CONCLUSIONS 
 
This paper presents a new model-based stochastic targeted (STAR) controller. The controller method 
is flexible for a wide range of clinical approaches. This research presents initial results from a trial in a 
Belgian ICU (STAR-Liege).  
 
Clinical results show that the controller is effective and safe, resulting in no hypoglycemic event (BG 
< 40 mg/dL) for the nine patients included in the pilot trial. Among the 205 BG measurements, only 
one was below 72 mg/dL (63 mg/dL). Controlled BG levels were tightly distributed. However, the 
pilot trial length of 24-hours was not designed to show long-term steady state control. Thus, despite 
every patient reaching 125 mg/dL, median BG values were slightly higher than the 125 mg/dL target. 
 
An important result was the observation that some patients were significantly more variable in their 
insulin sensitivity (SI) than expected from stochastic cohort models using all patient days of stay. New 
stochastic models were created to better account for this variability. The application of a stochastic 
model using only the initial 1-2 days of stay would have resulted in different, more continuous insulin 
interventions and better forecasting. Ongoing next-generation pilot trials are thus expected to account 
for this variability directly and should thus reduce the measurement rate seen here as a result. 
 
The overall results show tight, very safe control for post-cardiac surgery patients who exhibit signifi-
cantly enhanced variability. Thus, the fundamental stochastic targeted (STAR) concept has been 
shown to be safe and effective when adapted, within its control framework, for an insulin-only ap-
proach in this Belgian ICU. Specific issues to be modified to enhance performance and usability were 
identified in this short, proof-of-concept trial, and will be implemented in a next generation pilot trial.  
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Appendix 
 
A-1: Definition of the glucose-insulin system model. 
Equations (1) to (3) define the clinically validated model of the glucose-insulin system [31]. 
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(3) 
Where G(t) [mmol/L] is plasma glucose I(t) [mmol/L] is plasma insulin, uex(t) [mU/min] is exogenous 
insulin input, basal endogenous insulin secretion is IB [mU/L/min], with kI representing suppression of 
basal secretion by exogenous insulin. Interstitial insulin is Q(t) [mU/L], with k [1/min] accounting for 
losses and transport. Body and brain weight are denoted by mbody [kg] and mbrain [kg]. Endogenous 
glucose clearance is pG [1/min] and time-varying insulin sensitivity is SI or (formally) SI(t) in Equa-
tion (1) [L/(mU.min)]. Finally, VI,frac [L/kg] is the insulin distribution volume per kg body weight and 
VI the resulting volume [L], and n [1/min] is the transport rate of insulin from plasma. Total plasma 
glucose input is P(t) [mmol/min], endogenous glucose production is PEND [mmol/kg/min] and VG,frac 
[L/kg] represents the glucose distribution volume per kg body weight. CNS [mmol/kg/min] captures 
non-insulin mediated glucose uptake by the central nervous system. Michaelis-Menten functions mod-
el saturation, with αI [L/mU] for the saturation of plasma insulin disappearance, and αG [L/mU] for 
insulin-dependent glucose clearance saturation.  
 
A-2: The stochastic model for insulin sensitivity. 
The insulin sensitivity is the critical parameter in predicting the outcome of an insulin intervention. As 
insulin sensitivity is relatively variable hourly, modeling the changes in insulin sensitivity is quite 
important to improve assessment of the patient’s insulin response, and thus to allow more accurately 
targeted control. 
 
The goal of the stochastic model is to describe the hourly variations of the insulin sensitivity, based on 
clinically observed insulin sensitivity variations in ICU population data. First, clinical data (blood 
glucose, insulin and nutrition inputs) are used to identify hourly insulin sensitivity values using the 
glucose-insulin system model (A-1) [21]. If insulin sensitivity at hour n+1 and at hour n are denoted 
respectively by 𝑆𝐼,𝑛+1 and 𝑆𝐼,𝑛, the distribution of the hourly changes in 𝑆𝐼, (𝑆𝐼,𝑛 = 𝑥𝑖, 𝑆𝐼,𝑛+1 = 𝑦𝑖), 
can be assessed (Figure 8, left panel). Finally, a probability density of insulin sensitivity at hour n+1 
(𝑆𝐼,𝑛+1) taking on a value 𝑦 can be calculated by knowing insulin sensitivity at hour n (𝑆𝐼,𝑛), using 
identified variations from clinical data. This probability density function, 𝑝(𝑆𝐼,𝑛+1 = 𝑦|𝑆𝐼,𝑛 = 𝑥), de-
fined the stochastic model. An example is illustrated on the right panel in Figure 8. 
    
Figure 8 – On the left panel: hourly SI variation (dots). On the right panel: stochastic model of 𝑺𝑰 variation, probabil-
ity density function of 𝑺𝑰 
 
The stochastic insulin model can then be used to forecast likely blood glucose outcomes for a given 
intervention (a given insulin infusion), using the model defined by Equations (1) to (3). This approach, 
illustrated in Figure 9, allows the optimization of prediction and ensures safety, especially from hypo-
glycemia. 
 
Figure 9 - Distribution of BG outcomes based on the stochastic model for insulin sensitivity variations 
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